Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action

David R. Langley,1* S. Roy Kimura,1 Prasanna Sivaprapasam,1 Nannan Zhou,2 Ira Dicker,2 Brian McAuliffe,2 Tao Wang,3 John F. Kadow,3 Nicholas A. Meanwell,3 and Mark Krystal2

1 Computer Assisted Drug Design, Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut
2 Department of Virology, Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut
3 Department of Chemistry, Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut

ABSTRACT

HIV-1 gp120 undergoes multiple conformational changes both before and after binding to the host CD4 receptor. BMS-626529 is an attachment inhibitor (AI) in clinical development (administered as prodrug BMS-663068) that binds to HIV-1 gp120. To investigate the mechanism of action of this new class of antiretroviral compounds, we constructed homology models of unliganded HIV-1 gp120 (UNLIG), a pre-CD4 binding-intermediate conformation (pCD4), a CD4 bound-intermediate conformation (bCD4), and a CD4/co-receptor-bound gp120 (LIG) from a series of partial structures. We also describe a simple pathway illustrating the transition between these four states. Guided by the positions of BMS-626529 resistance substitutions and structure–activity relationship data for the AI series, putative binding sites for BMS-626529 were identified, supported by biochemical and biophysical data. BMS-626529 was docked into the UNLIG model and molecular dynamics simulations were used to demonstrate the thermodynamic stability of the different gp120 UNLIG/BMS-626529 models. We propose that BMS-626529 binds to the UNLIG conformation of gp120 within the structurally conserved outer domain, under the antiparallel β20–β21 sheet, and adjacent to the CD4 binding loop. Through this binding mode, BMS-626529 can inhibit both CD4-induced and CD4-independent formation of the “open state” four-stranded gp120 bridging sheet, and the subsequent formation and exposure of the chemokine co-receptor binding site. This unique mechanism of action prevents the initial interaction of HIV-1 with the host CD4+ T cell, and subsequent HIV-1 binding and entry. Our findings clarify the novel mechanism of BMS-626529, supporting its ongoing clinical development.

Proteins 2015; 83:331–350. © 2014 The Authors. Proteins: Structure, Function, and Bioinformatics Published by Wiley Periodicals, Inc.

Key words: antiretroviral; molecular dynamics; protein modeling.

INTRODUCTION

Antiretroviral drugs used to treat human immunodeficiency virus type 1 (HIV-1) infection can target several distinct steps within the viral lifecycle. Despite the range of antiretroviral agents available, there is a continued need for novel classes of drugs that target different stages of viral replication, primarily due to development of resistance to existing compounds, and a requirement for new agents to exhibit improved...
In the unliganded state, the bridging sheet strand order co-receptor binding results in further conformational changes and exposes a co-receptor binding site. Subsequent interaction of gp120 with the N-terminus of the cellular CD4 receptor. This results in conformational changes to gp120 that assemble and expose a co-receptor binding site. Subsequent co-receptor binding results in further conformational changes that culminate in gp41-mediated membrane fusion. The gp120 protein is highly dynamic, undergoing multiple conformational changes in solution, making understanding of its structure and conformational dynamics challenging. However, crystal structures of gp120 in both the unliganded “closed” (UNLIG) and CD4/monoclonal antibody-bound (LIG) states show that the gp120 core consists of an inner and an outer domain connected by a four-stranded β-sheet bridge domain. The bridging domain is composed of two strands from the outer domain (β20–β21) and two from the inner domain (β2–β3). In the unliganded state, the bridging sheet strand order is β2–β3–β21–β20, where strands β2–β3 and β21–β20 form anti-parallel sheets while β3–β21 is a parallel β-sheet. This bridging sheet arrangement stabilizes the closed state and directs the V1/V2 loops toward the crown of the trimer spike, where it packs against the V3 loop and buries the co-receptor binding site. However, in the CD4-bound structures, CD4 binds at a highly conserved site, composed of regions from the outer and bridging sheet domains. The interaction of gp120 with CD4 stabilizes changes in the β21–β20 sheet conformation that leads to “opening” of the trimer spike and re-ordering of the bridging sheet (β3–β2–β21–β20). This directs the V1/V2 loops toward CD4 and away from V3 to form and expose the co-receptor binding site. As the gp120–CD4 interaction represents the first step in CD4-dependent HIV-1 cell entry, the conserved CD4 binding site provides an attractive target for new antiretroviral agents. Currently, there are no approved agents that target this initial gp120–CD4 interaction.

Several small-molecule attachment inhibitors targeting the conserved CD4 binding region within gp120 have been described. A series of ketopiperazinamide-based small-molecule inhibitors are the most advanced. Optimization to improve the potency and pharmacokinetic profile of this class led to the discovery of BMS-626529. This molecule displays in vitro activity against HIV-1 envelopes with C-C chemokine receptor type 5 (CCR5)-, C-X-C chemokine receptor type 4 (CXCR4), and dual tropism. It also is active against almost all HIV-1 subtypes tested except for subtype CRF01-AE and possibly group O. BMS-626529 is administered as a phosphonooxymethyl ester prodrug, which was developed to improve the solubility and dissolution of BMS-626529. In an 8-day proof-of-concept study in treatment-naive and -experienced HIV-1-infected subjects (all with subtype B infection), treatment with BMS-626529 (delivered as BMS-663068 in an extended-release formulation) resulted in substantial declines in plasma HIV-1 RNA (maximum median decrease from baseline ranged from 1.21 to 1.73 log_{10} copies/mL). Viral envelopes from the proof-of-concept study exhibited substantial inter- and intrasubject variability in susceptibility to BMS-626529. However, emergent resistance was not observed on population genotyping or phenotyping.

Differing mechanisms of action are proposed for AIs; these are based on the observed activity against CD4-independent virus, direct inhibition of the virus–CD4 interaction, inhibition of CD4-induced changes in the gp120–gp41 structure, or by ordering of the unliganded “closed” trimer spike. Given the hypothesis that AIs interfere with the gp120–CD4 interaction, a potential resistance pathway for AIs is the emergence of CD4-independent virus; however, CD4-independent isolates are rarely isolated in vivo. Laboratory-derived envelopes with a CD4-independent phenotype (CXCR4- and CCR5-tropic) retain susceptibility to BMS-626529, while envelopes from viruses with substitutions associated with BMS-626529 resistance show no evidence of CD4-independent entry.

Although structures representing various conformations of simian immunodeficiency virus and HIV-1 gp120 exist, there is currently no structural information available for BMS-626529 bound to gp120. In this article we describe structural models representing four different conformational states of HIV-1 gp120. The models were constructed utilizing known X-ray structures of HIV-1 gp120, and guided by published cryo-electron tomography, cryo-electron microscopy, and small-angle X-ray scattering (SAXS) data. These models were used for docking and molecular dynamics (MD) studies with BMS-626529 in order to determine plausible compound-binding pose(s), and provide insight into the mechanism of action of this class of antiretroviral compounds.

### MATERIALS AND METHODS

#### Compounds

BMS-626529 and the earlier synthesized AIs (BMS-088, BMS-049, BMS-378806, BMS-488043) were prepared at Bristol-Myers Squibb.

#### Construction of homology models of unliganded, intermediate, and liganded HIV-1 gp120 structures

The gp120 sequence from the HIV-1 JRFL strain (UniProt identifier: Q75760) was used for homology modeling,
as it requires the least amino acid deletions or insertions within the published X-ray structures that were used as templates. However, in order to be consistent with the majority of published literature, the numbering of amino acids in gp120 within this study is based on the HIV-1 HXB2 reference strain sequence (UniProt identifier: P04578, residues 1–511). Residues 1–43 and 493–511 were not incorporated into the models to remove the dangling ends and reduce the size of the MD water box.

Construction of a homology model for liganded HIV-1 gp120 (LIG)

A variety of partial X-ray structures are available from the Protein Data Bank, representing multiple conformational states of gp120. In order to create a homology model of the liganded CD4-bound HIV-1 gp120 structure (LIG), three partial structures of HIV-1 gp120 (2B4C, 3JWD, and 3U4E) were superimposed and merged into a single structure using the protein design package in QUANTA (QUANTA Modeling Environment, release 2006, Accelrys Software Inc., CA). The resulting structure was missing part of the V1/V2 loop (amino acids 171–188), which was constructed using the Prime Homology Modeling Package (Suite 2011, Prime version 3.0, Schrödinger LLC, NY). CD4 and the X5 antibody from the 2B4C structure were retained (Fig. 1d) to complete the model.
the CD4-liganded gp120 core structures. In contrast, the full-length unliganded “closed state” gp120 structure observed in the cleaved HIV-1 envelope trimer differs from the unliganded core structure primarily in the ordering and positioning of the bridging sheet domain. This is due to restraints imposed by the V1/V2 and V3 loops, which are not present in the monomer core structure. In the CD4-bound structures and the unliganded core structure, the bridging sheet (Fig. 1c–d) has the following order: $\beta_3$–$\beta_2$–$\beta_21$–$\beta_20$, and $\beta_3$–$\beta_2$, $\beta_2$–$\beta_21$, and $\beta_21$–$\beta_20$; all form anti-parallel $\beta$-sheets. In this arrangement, W427, from the $\beta$-turn of the $\beta_21$–$\beta_20$ sheet, binds deep into the liganded W427 binding pocket forming the gp120 water channel and the CD4:F43 binding pocket (Fig. 2b) and directs the V1/V2 loops toward CD4 and away from V3. This allows the formation and exposure of the co-receptor binding site. It also opens up a large hydrophobic cavity between the outer domain and the bridging sheet.

In order to reduce the number of modeled amino acid side chains and loops, a homology model of the JRFL HIV-1 gp120 closed state was constructed from the HIV-1 gp120 crystal structures 2B4C and 4NCO. The structures were superimposed and residues 253–296 and 331–418, 445–492, and 4NCO residues 44–252 (inner domain), 297–330 (V3 loop), 419–444 ($\beta_20$–$\beta_21$ loop) were merged into a single structure using the protein design package in QUANTA (refer above). The resulting structure was missing parts of the V1/V2 loop (amino acids 135–139, 150, and 179–190), which were constructed using the Prime Homology Modeling Package (refer above).

To create a homology model of the CD4-bound intermediate (bCD4) state of HIV-1 gp120, the gp120 LIG structure was modified by replacing the V3 loop (residues 297–330) with the one from the 4NCO crystal structure. CD4 from the 2B4C structure was retained in the model. The gp120 pre-CD4 binding intermediate (pCD4) was constructed from the gp120 bCD4 by removing CD4 and adjusting the torsion angles of residues 116, 117, 202, and 203 to move the V1/V2 loops near the V3 loop in line with observations from SAXS.
Ligand docking

BMS-626529 has seven rotatable bonds (Fig. 3:1) and the piperazine moiety can adopt a “chair,” or the higher energy “twist boat” and “boat” conformations. All rotatable bonds except 4 and 7 have minima at ~0 and ~180 degrees. However, due to steric and electronic constraints, the methoxy at C4 and 3-methyltriazole at C7 adopt deeper minima, with the methoxy pointing away from the oxoacetamide while the triazole hydrogen bonds with the azaindole NH group. The oxoacetamide moiety (torsion-4, O=C-C=O) has a minimum between ±87.4 and ±119.8 degrees as determined from 49 small-molecule X-ray structures from this series. While the piperazine ring can adopt several forms, only the “up” (Fig. 3:1 and 3) and “down” (Fig. 3:2 and 4) chair was used as starting conformations for the docking studies. The benzamide torsion-7 (Fig. 3:1) has minima between ±49 and ±90 degrees, which were dependent on the piperazine ring conformation and crystal packing. This produced 16 unique conformations as starting points for docking studies.

Putative binding sites for BMS-626529 were identified following analysis of resistance mutation data, available AI structure–activity relationships (SARs), and biophysical and biochemical data, as described in the results and discussion section. Guided by these data, the 16 conformational forms of BMS-626529 were hand-docked and/or glide-docked into the gp120 water channel and CD4:F43 binding pocket that are present in the pCD4, bCD4 and LIG structures, and into the central hydrophobic cleft present within the HIV-1 gp120 UNLIG closed state. In addition, different side chain rotamers for amino acids W112, E370, N377, and N425 were used during the docking studies. For several of the glide docking studies into the UNLIG structure, hydrogen bond constraints with the Y384 side chain, and/or the backbone NH of N425, were given as options. The hydrogen bond constraints and side chain rotamers were selected based on MD refined hand-docked poses.

Thrombin digestion

Protease susceptibility testing and preparation of soluble CD4 (sCD4) and HIV-1 JRFL gp120 were performed as previously described by Ho et al. MD simulations

Each gp120 core/BMS-626529 complex was placed in a box of TIP3p water molecules with four sodium ions. The size of the box and the number of water molecules were determined by a minimum 9Å water layer covering
the protein complex. The MD simulation was carried out with the Nanoscale Molecular Dynamics (NAMD) package. The Amber f99SB-ILDN force field was used to model the protein, solvent and ions. A modified General Amber force field (GAFF) was used for BMS-626529 (see supplemental material). The Verlet integration and a 2/2/6 multitime step scheme were used and SHAKE was applied to all hydrogen bonds. The non-bonded interactions were tapered between 8 and 10 Å and a particle-mesh-Ewald (PME) method was used for long-range electrostatics. The simulation was run with periodic boundary conditions in an NPT ensemble at 300 K and 1 atm. The initial system was first relaxed with 250 steps of conjugate gradient minimization with the protein backbone constrained, followed by an additional 250 steps of unconstrained minimization. The MD simulation was heated in 10 K increments every 100 steps to 300 K (NVT ensemble) and equilibrated over 250 ps to the NPT ensemble. The MD production runs varied in length from 10 to 150 ns. Multiple simulations were run using different inhibitor docked poses. In some studies, selected constraints were used to test different hypotheses, and dihedral parameters for BMS-626529 were softened to enhance sampling. The simulations reported herein were performed without constraints.

**MD analysis**

MD snapshots were collected every picosecond for a data analysis. The stability of the MD for each model was monitored by root-mean-square deviation (RMSD) from the starting and mean structures using all heavy atoms of gp120 structure (amino acids 44–492). The RMSD for the inner domain utilized residues 44–119, 205–254, and 486–492, while the RMSD for the outer domain utilized residues 255–296, 331–362, 374–396, 413–421, 444–457, and 464–485; the variable loops, CD4 binding loop and V1/V2, V3 and bridging domain are in a non CD4-binding conformation and there is a large hydrophobic cavity under the bridging domain and within the outer domain. In the gp120 pCD4 (Fig. 1b), the β20–β21 sheet moves toward the CD4 binding loop and into the hydrophobic cavity present in the outer domain of the UNLIG state placing W427 deep in the liganded W427 binding pocket, thereby forming the gp120 water channel and CD:F43 binding pocket. The rearrangement of the β20–β21 sheet disrupts the UNLIG bridging sheet domain between the β3–β21 strands, which destabilizes the trimer envelope and allows it to open, and the bridging sheet to rearrange to the CD4-bound state. In the CD4-bound model (bCD4, Fig. 1c), the β3–β2 sheet is zipped up against the CD4-stabilized β21–β20 sheet, forming the rearranged β3–β2–β21–β20 bridging sheet. The formation of the reordered bridging sheet moves V1/V2 close to CD4 domains 1 and 2 to fully expose the V3 loop and partially form the chemokine binding site. In the fully liganded gp120 (LIG, Fig. 1d) the V3 loop opens to complete the formation and exposure of the chemokine binding site, which is occupied by the X5 antibody in Figure 1d.

In the UNLIG model there is no hindrance to CD4 binding. However, the gp120 CD4:F43 binding pocket is only partially formed and CD4 is expected to bind weakly or not at all. Based on HDX and single-molecule fluorescence resonance energy transfer (smFRET) imaging studies, the gp120 UNLIG, pCD4, bCD4 states are in equilibrium. However, the gp120 UNLIG state is predominant due to stabilization by the tertiary and quaternary structure of the bridging sheet and V1/V2/V3 loops. However, CD4 binding shifts the equilibrium to the gp120 bCD4 state by trapping and stabilizing the β20–β21 sheet in the CD4 bound conformation. The CD4-stabilized rearrangement of the β20–β21 sheet, from the UNLIG (off position) to the bCD4 (on position), breaks the hydrogen bonding interactions between the β3–β21 strands, leading to the disruption of the UNLIG bridging sheet domain and the opening of the trimer envelope.

**Identification of putative BMS-626529 binding sites within HIV-1 gp120**

**Substitutions that affect susceptibility of HIV-1 to BMS-626529**

In order to identify a putative binding site for BMS-626529, the amino acid positions of substitutions in gp120 linked to decreased susceptibility to AIs were mapped onto the gp120 UNLIG, pCD4, and bCD4 models (Fig. 2). These included substitutions shown to reduce susceptibility to BMS-626529 (S375, M426, M434, M475) and an earlier-generation AI, BMS-488043 (V68, L116, S375, M426). In addition, the amino acid positions of gp120 substitutions shown to reduce susceptibility to earlier-
structure–activity relationship (SAR)

SARs across the AI series were used to help identify the most plausible binding model. The BMS-626529 HIV-1 gp120 binding site must be able to accommodate a wide range of structural diversity within the AI series. Figure 4 shows structural motifs that were widely used in earlier AIs in the series that led to the identification of BMS-626529. The putative binding sites identified within the hydrophobic cleft in the outer domain of gp120 and CD4:F43 binding pocket only appeared to be present in the gp120 pCD4, bCD4 and LIG models.
the gp120 water channel/CD4:F43 binding pocket were compared against the full range of SARs for the AI series in order to determine their feasibility.

The proposed binding site for BMS-626529 within the gp120 water channel/CD4:F43 binding pocket did not accommodate the entire spectrum of structural motifs shown in Figure 4 (specifically, the 4-(diphenylmethylene) piperidine and the C7 2-amino-benzimidazole carboxamide moieties). In addition, the BMS-488043 C7-antibody conjugates described by Sato et al.68 and the 4'-methoxy indole attachment inhibitor with a C-7 furanyl PEG-DNP69 are not compatible with the model of AI binding within the gp120 water channel/CD4:F43 binding pocket in the gp120 UNLIG model. In contrast, the putative BMS-626529 binding site within the central hydrophobic cavity present in the gp120 UNLIG model was compatible with the entire range of observed SARs, suggesting that this model of compound binding has increased relevance.

**Biochemical probing of binding site flexibility and binding mode**

Conformational changes in HIV-1 gp120 induced by AIs were measured through the ability of thrombin to cleave within the V3 loop of gp120. Thrombin-mediated cleavage of sCD4-bound gp120, unbound gp120, and gp120 bound to the AIs BMS-088, BMS-049, BMS-378806, and BMS-488043 was measured over a period of 50 h (Fig. 5a). Differences in susceptibility of the V3 loop to thrombin were seen between CD4-bound gp120, unbound gp120, and gp120 bound to the AIs. Relative rates of cleavage were as follows: CD4-liganded gp120 (16×) > BMS-049-bound gp120 (10×) > BMS-088-bound gp120 (7.1×) > unbound gp120 (4.5×) > BMS-488043-bound gp120 (2.5×) > BMS-378806-bound gp120 (1.0×). The rate of cleavage roughly correlated with the size of the moiety at the AI C7 position (Fig. 5b). This places directional constraints on the ligand binding mode, as C7 would need to be in a position to affect the V3 loop exposure, and at the same time, would need to be able to accept large substitutions up to the size of a linked antibody (in line with a recent study by Sato et al.).68 These data provide further evidence to support the proposed binding of BMS-626529 to the unliganded (gp120 UNLIG) conformation of gp120, and are not compatible with the proposed model of BMS-626529 binding within the gp120 water channel found in the pCD4, bCD4 and LIG conformations of gp120.

**Biophysical data**

Further support for the model of AI binding to the gp120 UNLIG structure comes from studies by Si et al.28 and Myszka et al.70 Here, thermodynamic changes in HIV-1 gp120 were measured upon binding of an earlier AI, BMS-378806, or binding of sCD4. Interaction of BMS-378806 with gp120 was characterized by a binding enthalpy of –3.4 ± 0.5 kcal/mol and a binding entropy of 22 ± 2 cal/(K × mol),28 which contrasted with the extremely large enthalpy and entropy changes associated with binding of sCD4 to gp120, and the significant restructuring of gp120 following sCD4 binding.70 The observed thermodynamic signature associated with binding of BMS-378806 supports a model in which the binding site is conserved across multiple states, which is in line with the presence of the structurally conserved hydrophobic cleft in the outer domain in the gp120 UNLIG state and exposed in the gp120 LIG state during an induced fit docking study by Parker et al.69 In contrast, binding of the AI within the gp120 water channel and CD4:F43 binding pocket in the gp120 LIG, pCD4
and bCD4 states would result in the restructuring of gp120. The large amount of gp120 restructuring that this binding model would require is inconsistent with the observed thermodynamic signature for AI binding. In addition, a recent study shows that BMS-378806 slows the rate of hydrogen deuterium exchange within gp120. It achieves this by binding with and stabilizing the closed trimer envelop complex. In contrast, NBD-556, which is a CD4 mimetic that binds within the gp120 water channel and CD4:F43 binding site, led to faster exchange.

Docking of BMS-626529 into the gp120 UNLIG model

BMS-626529 was docked into the central hydrophobic cavity present within the outer domain of the gp120 UNLIG model, as guided by AI SAR analysis, susceptibility studies, and biochemical data. When docked into the central cavity, BMS-626529 was surrounded by amino acid residues that represent the location of clinically- and laboratory-derived substitutions known to confer decreased susceptibility to BMS-626529 and/or the earlier AIs in the series (Fig. 6). In all of the docked models that gave a minimal fit to the criteria described above, the oxoacetamide dihedral angle (O=C–C=O torsion 4 (Fig. 3:1) is between −80 and −120 degrees. The substituted azaindole was positioned next to the CD4-binding loop to fill the space in the binding site required for CD4:F43 binding (Figs. 6 and 7), and the benzamide moiety was near α2 of the inner domain under the β20–β21 sheet and gp41. This general binding pose places the oxoacetamide moiety near the side chain of Y384 and the backbone NH of N425, allowing for hydrogen bonding interactions. However, binding pose sub-states are also readily accommodated. For example, the benzamide can be positioned near W112 and M426, while rotation of torsion angle-6 (Fig. 3:1) to the other minimum places it near V255 and N377. It should be noted that anals containing the 4-(diphenylmethylene) piperidine moiety (Fig. 4) would simultaneously occupy both of these positions. Rotation of torsion-5 inverts the piperazine chair from an up- to a down-chair, and when combined with torsion-6 rotations, produces four unique binding poses. This group can be expanded to eight binding poses by simply rotating torsion-3 between its two minima. In the first set of four poses (Set-1), the AI is docked with the C4-methoxy pointing toward the piperazine ring and the C4-methoxy group is buried deep in the hydrophobic cleft, positioned near T257 and S375. In addition, the azaindole C5, N6, and the triazole C5’ positions occupy a position near G473, D474, and M475. This explains why substitution at these positions results in reduced activity. Rotation of torsion-3 to the other minimum generates a second set (Set-2) of four poses and points the azaindole out of the pocket, through the space between the β20–β21 sheet and the CD4-binding loop. In this orientation of the azaindole,
when the structure is inverted. Despite these restrictions, some members of the AI series, such as BMS-378806 and BMS-488043, could be docked into the water channel present in the gp120 pCD4, bCD4, and LIG models. While we cannot rule out the possibility of multiple binding modes for different members of the AI compound collection, a unified model that binds the majority of compounds from this congeneric series seems more likely. Thus, only models of BMS-626529 bound to the UNLIG conformations of gp120 were taken forward for evaluation and analysis in MD simulation studies.

**MD simulations and refinement of docked poses**

Multimicrosecond (μs)-long MD simulations show that compounds can spontaneously and correctly dock into some protein families. In these studies, the compound moves around in the solvent where it samples a large set of conformational and solvation states until it finds and enters the binding vestibule. From the binding vestibule, the ligand can either re-enter the solvent or sample with the protein target a smaller subset of conformational and solvation states until it enters the binding site. Once in the binding site, the protein, ligand, and environment continue to sample smaller and smaller states as the complex settles into the bound state or an ensemble of bound sub-states. The goal of the docking study presented here is to accelerate the ligand entry into the binding site and let the MD refine the binding pose(s). Thus, multiple MD simulations on the 25–150 ns timescale were conducted to test the dynamic stability of the BMS-626529-docked models and examine the interactions between BMS-626529 and residues at positions within gp120 associated with substitutions known to reduce susceptibility to AIs. These simulations were performed in explicit solvent, using the gp120 UNLIG/BMS-626529 docked poses discussed above as starting structures.

As expected from the results of earlier structure and HDX studies, the MD mean gp120 structures differed from simulation to simulation as larger fluctuations were observed in the inner domain, the variable loop, segments of the CD4-binding loop, and the β20–β21 sheet. Two starting poses from Set-1 converged over the course of the simulation to a common dynamic AI binding pose, with the caveat that the protein from each simulation had structural differences. One pose from Set-2 settled into a stable simulation. The remaining binding poses either partially exited the gp120 binding site (re-entered the binding vestibule), or induced large structural distortions in gp120 and were discarded as potential binding models. The following will focus on the two models from Set-1 that strongly fit with the SAR for this AI series and the one model from Set-2 that stabilized.
**Accelerated sampling of gp120 UNLIG/BMS-626529 Set-1 simulation**

To further accelerate the ligand sampling within the binding site, MD simulations were carried out with soft torsion parameters on the four bound poses from Set-1. The goal of this study was to determine if the benzamide has a preferred location within the binding site, and to determine if there is room within the binding site for BMS-626529 to rearrange to the preferred conformation. In the two models where the phenyl ring of the benzamide moiety was initially docked near V255 and N377, the amide flipped to move it near W112 and M426 between 16 and 19 ns (down) or 37 and 39 ns (up), depending on the initial piperazine ring conformation. In both simulations, the amide flip occurred through a piperazine twist-boat conformation and pyramidal benzamide nitrogen. The phenyl ring moved through an arch from a position near V255 and N377, past F210 and F382, to end in a position close to W112 and M426. Only minimal movement was observed in the two simulations that started with the phenyl group of the benzamide moiety near W112 and M426. Once equilibrated, all four simulations remained semistable throughout the remainder of the 100-plus-nanosecond simulations, with the piperazine ring flipping from chair-to-chair, and the oxoacetamide moiety hydrogen bonding with the side chain of Y384 and backbone NH of N425 and occasionally K421. The two structures with the benzamide starting near W112 and M426 show tight convergence, while the other two differed in the pucker of the piperazine ring and placement of the benzamide group. All four structures differ in the protein structures as larger fluctuations were observed in layer 1 of the inner domain, all of the variable loop, portions of the CD4-binding loop, and the β-turn residues of the β20–β21 sheet (Supporting Information Fig. S1). The differences observed in the AI conformations of the MD mean structures (Supporting Information Fig. S1) were attributed to differences in protein conformations, soft AI parameters and incomplete sampling. While the MD simulations identified a preferred orientation for the benzamide moiety, they also highlight the accessible room within the binding site required to accommodate the 4-(diphenylmethylen) piperidine and 4-(phenylacrylonitrile) piperidine moieties (Fig. 4).

**gp120 UNLIG/BMS-626529 Set-1:1, Set-1:2 and Set-2:3 simulations**

The RMSD between the simulation frames and the starting coordinates/MD mean coordinates for the gp120 UNLIG/BMS-626529 simulations starting from docked poses of Set-1:1 (Fig. 6a), Set-1:2 (Fig. 7) and Set-2:3 (Fig. 6b and Fig. 3:3 with rotation of torsion-3 to the other minimum) are illustrated in Figure 8. In all three simulations, the structure drifted away from the initial model (Fig. 8a–c, red) over the first 15 to 20 ns, where it stabilized and fluctuated about the MD mean conformation (Fig. 8a–c, yellow). A large portion of the drift that occurred in the first 15 ns was due to the rearrangement of the inner domain, the variable loop, segments of the CD4-binding loop, and the β-turn residues of the β20–β21 sheet, as the structure moved away from the conformation observed in the trimer spike complex. The large fluctuations observed in these regions of HIV-1 gp120 are in agreement with results from earlier structures8,9,11,32–37 and HDX studies.7,12,13 Even with the variable loops, segments of the CD4-binding loop, and the β20–β21 sheet excluded from the RMSD analysis, a large drift was observed for the HIV gp120 core (Fig. 8a–c, green). The largest contributor to the drift is the inner domain (Fig. 8a–c, brown), while the structurally conserved outer domain showed minimal drift and stabilized within the first 5 ns of the simulations (Fig. 8a–c, pink). Similar to the accelerated simulations, the MD mean gp120 structures differ from simulation to simulation, due mostly to the larger fluctuations observed in the inner domain, the variable loop, segments of the CD4-binding loop and the β-turn residues of the β20–β21 sheet. The key difference between the three runs is associated with the conformation of BMS-626529. In the Set-1:1 and 2 simulations, the piperazine ring is in different chair configurations, which results in a slightly different placement of the benzamide group.

In the Set-1:1 simulation (Fig. 6a and Fig. 3:1), the up-chair conformation stabilized within the first nanosecond. BMS-626529 fluctuated about the starting conformation, which is only slightly offset from the MD mean conformation (Fig. 8a, blue, light blue) throughout the remainder of the simulation, with occasional sampling of the twist-boat and down-chair conformation.

In the Set-1:2 simulation (Fig. 7 and Fig. 3:2), the AI piperazine ring started in the down-chair conformation. In this simulation, the AI took about 15 ns to equilibrate and become semistable. For the remainder of the simulation, BMS-626529 fluctuated about the starting and MD mean conformation (Fig. 8b, blue, light blue) with the piperazine ring continually flipping between the up-chair, twist-boat and down-chair conformation (Fig. 8b, blue). Despite lower overall drift in the protein and inhibitor observed in the Set-1:1 simulation, a notable kink slowly developed in α2 of the inner domain over the first 20 ns that rapidly vanished between 24 and 28 ns. Once equilibrated, the two Set-1:1 and 2 simulations showed tight convergence with respect to the HIV-1 gp120 and BMS-626529 interactions. The AI oxoacetamide moiety forms nearly continuous hydrogen bonds with the side chain of Y384 and backbone NH of N425 and occasionally the side chain K421. This occurred while the phenyl group of the benzamide moiety fluctuated near I108, I109, and W112 from α2 of the inner
domain and M426 from the β20–β21 sheet. In the Set-2:3 simulation (Fig. 6b and Fig. 3:3) with rotation of torsion-3 to the other minimum), the starting AI docked pose placed the phenyl ring of the benzamide near V255 and N377, the piperazine ring is in the up-chair, and the azaindole is docked between the β20–β21 sheet and the CD4 binding loop. BMS-626529 took about 20 ns to equilibrate and stabilize. During the simulation it only sampled the down-chair conformation two times (Fig. 8c, blue, light blue). During the equilibration period, the β-turn residues of the β20–β21 loop moved over the inhibitor where the following side chain-to-backbone hydrogen bond pairs stabilized it: W427-Q105, Q428-G473, or M475, and benzamide carbonyl W475. Once the complex equilibrated, it remained stable for the remainder of the 100-plus-nanosecond simulation.

In all of the simulations, the MD mean protein structures differ as larger fluctuations were observed in the inner domain, the variable loop, and portions of the CD4 binding loop and the β-turn residues of the β20–β21 sheet (Supporting Information Figs. S1 and S2). Videos of the last 10 ns of the Set-1:1, Set-1:2, and Set-2:3 simulations are provided in supporting material S3, S4, and S5, respectively.

gp120 UNLIG/BMS-626529 Set-1:3 and Set-1:4 simulations

The Set-1:3 and 4 simulations (Figs. 3:3 and 4), where the phenyl ring of the benzamide group was docked near V255 and N377, only remained stable for a few nanoseconds. BMS-626529 slowly worked partially out of the
binding site as water molecules move in and under the AI azaindole and oxoacetamide moieties to break the hydrogen bonds between the side chain of Y384 and backbone NH of N425. The binding pose with the down chair conformation (Fig. 3:4) remained semistable for ~50 ns, but left the binding site with a similar path as the up chair pose (Fig. 3:3). Both molecules rotated as a unit, with the azaindole ring moving between the CD4-binding loop and the residues 470–473, while the phenyl group of the benzamide moiety moved near W112 and M426. For the remainder of the 100-plus-nanosecond simulations, the AI benzamide moiety remained anchored near W112 and M426, while the azaindole/triazole moieties floated in the pocket near the CD4 binding loop and residues 470–473.

**BMS-626529/gp120 interactions**

Throughout the gp120 UNLIG/BMS-626529 MD simulations, BMS-626529 remained firmly seated in the central hydrophobic cavity of gp120 and under the β20–β21 sheet, blocking it from folding into the CD4-binding conformation and forming the four-stranded (β3–β2–β21–β20) bridging sheet that is required for formation and exposure of the chemokine receptor binding site. Consistent with the favorable entropy observed with gp120/BMS-378806 binding, these models suggest an adaptable binding mode that persists within multiple substates of UNLIG gp120.

Throughout the course of both the accelerated and normal MD simulations, BMS-626529 made close contact with a range of amino acid residues associated with...
both clinical and laboratory-generated substitutions known to decrease susceptibility to AIs. This was despite the high level of conformational sampling of the β-turn residues of the β21–β20 sheet that persisted throughout all of the simulations.

Distance plots for BMS-626529 and specific gp120 amino acids linked to key clinical and laboratory-generated resistance substitutions are shown in Figure 9. In the models, gp120 residues W112, T257, S375, F382, M426, W427, and M475 made direct contact with BMS-626529 throughout the simulations, while L116 made direct contact with W112, which in turn packed against the benzamide ring of BMS-626529. Mean distances between BMS-626529 and gp120 amino acids in the simulations are shown in Table I. The V68 and M434 residues lie outside of the binding site and distal to BMS-626529. While M434 is involved in bridging sheet packing (see below), V68 is on the outer edge of the inner domain and in close proximity to the region of gp41 that exits in the central cavity of the timer spike in the poorly formed CD4 binding site of the UNLIG state. Changes at V68 likely affect the projection and stability of the gp41 residues that spill into the CD4 binding site. Due to the very close proximity of gp41 and the β-turn residues of the β20–β21 sheet in the X-ray structure of the trimer spike, it is probable that gp41 influences the conformational sampling of the β20–β21 sheet and turn residues (Fig. 7).

The BMS-626529/gp120 interactions observed in the MD models are supported by previous site-directed mutagenesis studies. In the MD models, BMS-626529 extends over T257 and S375 and packs against the CD4-binding loop. In a study by Madani et al., substitutions at both T257 and S375 produced varying declines in viral susceptibility to an earlier AI, BMS-378806.47 The reduction in susceptibility was dependent on the substitution. For example, a >45-fold reduction in susceptibility (non-detectable inhibition) was observed when substitutions

### Table I
Mean Distances Between BMS-626529 and gp120 Amino Acids During Molecular Dynamics Simulations Carried out Starting from Different Docked Poses of BMS-626529 Bound to the Unliganded (UNLIG) gp120 Model

| Labels | Set-1:1 Mean distance | SD | Set-1:2 Mean distance | SD | Set-1:2 Mean distance | SD | Set-2:3 Mean distance | SD | Description |
|--------|-----------------------|----|-----------------------|----|-----------------------|----|-----------------------|----|-------------|
| V68    | 14.30                 | 1.39| 13.13                 | 0.62| 13.61                 | 0.74| b                     |
| I108   | 5.26                  | 1.17| 4.54                  | 0.61| 4.30                  | 0.41| c                     |
| I109   | 6.28                  | 1.45| 4.07                  | 0.47| 3.46                  | 0.21| c                     |
| W112   | 4.55                  | 1.51| 3.59                  | 0.34| 3.85                  | 0.49| c                     |
| D113   | 8.73                  | 1.56| 7.70                  | 0.87| 6.83                  | 0.54| c                     |
| L116   | 9.01                  | 1.32| 8.90                  | 1.38| 8.03                  | 0.60| b                     |
| A204   | 14.26                 | 1.62| 13.16                 | 0.89| 15.27                 | 0.66| c                     |
| V255   | 3.34                  | 0.31| 3.51                  | 0.28| 3.97                  | 0.39| c                     |
| T257   | 3.84                  | 0.33| 3.68                  | 0.30| 5.73                  | 0.59| c                     |
| D368   | 8.64                  | 2.42| 7.36                  | 1.15| 6.57                  | 0.76| c                     |
| F382   | 5.20                  | 1.91| 7.25                  | 0.43| 6.91                  | 0.57| c                     |
| E370   | 5.33                  | 2.26| 5.92                  | 1.14| 7.11                  | 1.44| c                     |
| I371   | 5.67                  | 2.26| 5.92                  | 1.14| 7.11                  | 1.44| c                     |
| S375   | 3.65                  | 0.40| 3.90                  | 0.55| 4.82                  | 0.45| a,b                   |
| N377   | 6.36                  | 0.40| 6.36                  | 0.55| 7.21                  | 0.86| c                     |
| F382   | 3.46                  | 0.23| 3.39                  | 0.17| 4.10                  | 0.74| c                     |
| Y384   | 2.93                  | 0.73| 2.90                  | 0.22| 3.14                  | 0.28| c                     |
| K421   | 4.25                  | 1.22| 3.80                  | 0.69| 3.47                  | 0.82| c                     |
| I423   | 4.83                  | 0.47| 5.22                  | 0.37| 4.26                  | 0.57| c                     |
| I424   | 3.51                  | 0.19| 3.49                  | 0.19| 3.44                  | 0.23| c                     |
| N425   | 2.99                  | 0.16| 2.96                  | 0.15| 3.05                  | 0.12| H-bond                |
| M426   | 3.49                  | 0.18| 4.22                  | 0.71| 3.90                  | 0.35| a,b                   |
| W427   | 3.77                  | 0.38| 3.68                  | 0.47| 3.03                  | 0.20| c                     |
| M434   | 9.05                  | 0.59| 8.91                  | 0.52| 9.42                  | 0.32| a                     |
| G473   | 3.47                  | 0.62| 3.64                  | 0.48| 4.03                  | 0.76| c                     |
| D474   | 4.73                  | 0.94| 3.79                  | 0.70| 5.19                  | 1.06| c                     |
| M475   | 3.59                  | 0.62| 3.38                  | 0.30| 3.73                  | 0.26| a                     |
| I109—W427 | 4.35              | 1.68| 3.85                  | 0.37| 3.72                  | 0.21| d                     |
| W112—W427 | 6.35              | 2.91| 7.78                  | 0.84| 7.72                  | 0.71| d                     |
| V255—W427 | 7.91              | 0.74| 7.24                  | 1.11| 7.06                  | 0.59| d                     |
| M475—W427 | 4.13              | 0.66| 3.85                  | 0.78| 3.64                  | 0.27| d                     |
| L116—W112 | 3.34              | 0.32| 3.08                  | 0.18| 3.08                  | 0.19| d                     |

Contact distance is considered to be ≤5 Å.

| = Site of clinically derived BMS-626529 resistance substitution.
| = Site of clinically derived BMS-488043 resistance substitution.
| = Site of laboratory-derived resistance substitution linked to reduced susceptibility to earlier AIs.
| = W427 pocket.
with large amino acids occurred at positions T257 or S375. Only 7-fold and 18-fold reductions in susceptibility occurred with smaller amino acids at positions T257A and T257G. These relative changes in susceptibility are consistent with the loss of a hydrogen bond between the CD4-binding loop and T257A (destabilizing the CD4-binding loop which packs the AI), and the additional loss of van der Waals contact between the AI and T257G. In addition, substitution with amino acids containing large side chains at either T257 or S375 would reduce the size and shape of the binding site in this model and would physically block AI binding.

In the MD models, W427 sits over the AI and π-stacks with the azaindole moiety periodically during the simulation. Site-specific substitutions at W427 are shown to either enhance the activity of AIs against HIV-1 (W427F; twofold) or lead to a complete loss in both sCD4 and AI binding (W427V). These changes would fit with a model in which the unliganded “closed” conformation of gp120 (UNLIG) is in equilibrium with pCD4, with residue W427 from the β20–β21 sheet moving in and out of the “liganded W427 pocket.” With a W427F substitution, the smaller phenylalanine residue would not completely fill the “liganded W427 pocket” and is predicted to shift the equilibrium toward the gp120 UNLIG state, which would favor AI binding as W427F could still π-stack with the azaindole moiety of the AI. Alternatively, substitution with a small, nonaromatic, and branched valine residue (W427V) is predicted to strongly shift the equilibrium away from the gp120 pCD4 and bCD4 states, thereby blocking CD4 binding. In this scenario, the smaller branched side chain would no longer make sufficient contact with the AI to support binding.

In line with the direct contact of residues W112 and F382 with BMS-626529 in the MD models, W112A and F382L substitutions are shown to cause a >45-fold decrease in susceptibility of HIV-1 to AIs (nondetectable inhibition). This decrease in susceptibility is consistent with a loss of interactions due to substitution with amino acids containing a small side chain.

Throughout the simulations, hydrogen bonds were intermittently formed between BMS-626529 and gp120 residues Y384 phenol and N425 backbone NH (Fig. 9, dark orange and black). While there is currently no experimental data to support the Y384 interactions, the N425A change resulted in a 3.7-fold improvement in susceptibility that may be explained by improved access to the backbone NH for hydrogen bonding, i.e. one of the N425 rotamers blocks the AI approach to the backbone NH.

In addition to the site-directed mutation data, data from a tryptophan fluorescence-quenching binding assay reported by Guo et al. showed a concentration-dependent reduction in gp120 tryptophan fluorescence upon titration of BMS-378806 into a solution containing monomeric gp120RFL protein. This leveled off at a ratio of approximately 1:1 BMS-378806 to monomeric gp120RFL, further supporting a model in which BMS-626529 interacts with one or more tryptophan residues.

**MD models and clinically important substitutions**

In an 8-day monotherapy study of BMS-626529 (administered as prodrug BMS-663068) in HIV-1 infected subjects, minimal change was seen in the susceptibility of the virus to BMS-626529. Also, during the course of the study there was no evidence of any known AI resistance mutations, as assessed by standard population-based phenotypic and genotypic approaches. Despite this, there were 6 of 48 subjects on study that were classified as nonresponders (defined as a viral load drop of <1 log_{10} copies/mL during treatment). Nonresponse was associated with lower baseline susceptibility to BMS-626529 and the key baseline substitutions in gp120 that contributed to this reduction in susceptibility were S375M, M426L, M434I and M475L. Of these, S375, M426, and M475 reside in the modeled binding site, while M434 is distal to the inhibitor. In the MD models, residues S375, M426, and M475 make direct contact with the AI throughout the MD simulation, with S375 lying under the C4-methoxy, M426 over the piperazine ring and M475 adjacent to the benzamide-piperazine moieties of BMS-626529. Changes at S375 should lead to a loss of van der Waals and potential hydrogen bonding interactions between BMS-626529 and gp120, and substitutions to amino acids with large side chains, for example, S375M, should physically hinder AI binding. Likewise, the change to amino acids with large branched side chains at positions 426 and 475, for example, M426L and M475I, would decrease the size of the binding site, which could reduce AI binding. The M434I substitution occurs outside of the AI binding site, but is present in the β21 strand of the β20–β21 sheet. In the UNLIG “closed state” the side chain of M434 packs against the side chains of V200, T202, I423 that are in the β3 and β20 strands, respectively, and forms two backbone hydrogen bonds with I201 and Q203 of β3 in forming the β3–β21 anti-parallel sheet. The M434 change to a branched side chain will minimally result in a distortion of the UNLIG “closed state” bridging sheet. This could shift the gp120 equilibrium away from an effective AI-binding conformation (gp120 UNLIG) and/or toward the pre-CD4-binding conformation (gp120 pCD4), thereby blocking formation of the AI binding site.

**Proposed model for binding of BMS-626529 to HIV-1 gp120 and proposed mechanism-of-action for BMS-626529**

The transition between gp120 states in the homology models and the proposed mechanism of action of BMS-626529 are summarized in Figure 10. The initial unliganded conformation of gp120 (gp120 UNLIG, Fig. 10:i)
is thought to be the predominant form in the gp120/gp41 trimer spike ensemble after cleavage of gp160 into gp120 and gp41. In the gp120 UNLIG state, the bridging sheet is ordered $\beta_2$-$\beta_3$-$\beta_21$-$\beta_20$ and directs the V1/V2 loops to pack against the V3 loop where they collectively form the quaternary structure of the trimer spike crown. In this state the $\beta_21$-$\beta_20$ sheet is misfolded for optimal CD4 binding. Note: the $\beta_21$-$\beta_20$ sheet is in equilibrium between nonCD4 and CD4 binding conformations with the nonCD4 binding conformations being the dominant form. In the gp120 pre-CD4 state (pCD4) the $\beta_2$-$\beta_3$-$\beta_21$-$\beta_20$ bridging sheet is disrupted and the $\beta_21$-$\beta_20$ sheet is in equilibrium between nonCD4 and CD4 binding conformations. Based on SAXS data, this is likely to be the predominant form of the gp120 monomer in solution. Note that in the absence of CD4 (1), (2), (3), and (5) are in equilibrium but due to tertiary and quaternary structure involving the bridging sheet and the V1/V2/V3 loops (1) is far more prevalent; however, in the lab-adapted ADA S190R/N197S virus, the population of (2), (3) and (5) are elevated, leading to CD4-independent attachment via (5). In the CD4-bound state (bCD4) CD4 stabilizes the $\beta_21$-$\beta_20$ sheet in the CD4 binding conformation and the re-ordered bridging sheet forms ($\beta_3$-$\beta_2$-$\beta_21$-$\beta_20$) moving the V1/V2 loops near CD4 domains I and II. 4. In the gp120 LIG state the V3 loop has opened to complete the formations and exposure of the chemokine binding site. 1a. BMS-626529 and related AIs are predicted to bind within the structurally conserved region in the outer domain of gp120 UNLIG (1) state. AIs binding within this pocket stabilize the UNLIG state by blocking the $\beta_21$-$\beta_20$ sheet from folding into a CD4-binding conformation and occupy the space next to the CD4 binding loop required for CD4:F43 binding, which blocks CD4 binding and the formation of the gp120 pCD4 state and all downstream events.
change in the β21–β20 sheet forms the gp120 water channel and CD4:F43 binding pocket, but at the cost of disrupting the unliganded bridging sheet. CD4 can readily be docked with the gp120 pCD4 state and would shift the equilibrium away from the UNLIG state toward the gp120 pCD4 state. The formation of the CD4/gp120 pCD4 complex results in stabilization of the CD4-binding loop and β20–β21 sheet.7,12,13 The stabilized disruption of the unliganded bridging sheet leads to opening of the V1/V2/V3 crown and the re-ordering of the bridging sheet to form the gp120/CD4 (bCD4, Fig. 10:3) complex. The formation of the gp120 bCD4 state (Fig. 10:3) marks the transition to the gp120 LIG state. In the gp120 bCD4/pCD4 complex (Fig. 10:3), the β2–β3 sheet is zipped up against the stabilized β20–β21 sheet, forming the four-stranded (β3–β2–β21–β20) bridging sheet, and the V1/V2 loops are moved near CD4 domains 1 and 2. These changes result in the partial formation and exposure of the chemokine receptor-binding site. The final conformational changes occur during the formation of the gp120 LIG/CD4 complex (Fig. 10:4) and the V3 loop opens to expose fully the chemokine receptor-binding site. Based on these models, CD4 carries out three functions for viral entry: (1) CD4 binds with gp120 to attach the virus to the CD4+ T cell; (2) CD4 binding promotes the opening of the trimer complex by stabilizing the β20–β21 sheet in the “on” positions and the disrupted unliganded bridging sheet; and (3) CD4 provides a template to facilitate the formation of the re-ordered liganded bridging sheet. Due to the close proximity of the gp41 HR1 and FPPR regions to the CD4 binding site in the trimer complex, CD4 may also play a role in priming gp41 once the complex binds with the chemokine receptor.

Based on the homology models constructed, we have described a simple four-state pathway (UNLIG – pCD4 – bCD4 – LIG) that is supported by the recent smFRET results.3 However, it is clear from the number of antibody-bound states described in the literature9,32–35 and the absence of highly immunogenic structures, that the pathway between the unliganded (closed) and liganded (open) states is composed of a continuum of substates that are separated by a high transition barrier occurring between the UNLIG and LIG states. CD4 binding with gp120, or mutations in gp120 that lead to CD4-independent virus,76 lower the transition state barrier allowing gp120 to form the LIG conformation in which the co-receptor binding site is formed, exposed, and co-receptor binding can occur. In agreement with our model, the HDX data highlight the flexible nature of the unliganded states of gp120 (UNLIG and pCD4). Specifically, the V1/V2 stem (β2–β3), the β20–β21 sheet, CD4 binding loop, and the reduced flexibility in these regions following CD4 binding and formation of the gp120 bCD4 state.7,12,13

Following validation and refinement of BMS-626529-docked models, we propose that BMS-626529, and related AIs, bind within the structurally conserved hydrophobic cavity in the outer domain of gp120, present in the UNLIG (Fig. 10:1a) conformation of gp120, just underneath the β20-β21 sheet, and adjacent to the CD4 binding loop. In this binding model, the AI stabilizes the “closed” UNLIG state by preventing the closed-state bridging sheet from being disrupted. Although movement of the β20–β21 sheet β-turn residues (M426-V430, within the AI/gp120 UNLIG complex) can still occur, subsequent rearrangement of the β20–β21 sheet into the CD4-binding-competent gp120 pCD4 state is blocked. In addition, the overlay of CD4 onto the BMS-626529/ gp120 UNLIG complex (Fig. 7) shows nearly complete overlap of the CD4:F43 side chain and the AI 7-(3-methyltriazole) azaindole moiety. There also is overlap when BMS-626529 is replaced with BMS-378806 (data not shown), but less so due to the smaller N7-azaindole. This model is consistent with direct inhibition of CD4 binding weakly to the nonoptimal CD4 binding site in the gp120 UNLIG state. The model also fits with previous data from Ho et al.,15 who suggested that binding of an AI can stabilize a conformation of gp120 that does not recognize CD4. Based on the homology modeling and compound docking reported in this study, it is likely that this conformation represents the gp120 UNLIG state.

A recent study by Li et al.31 demonstrated that laboratory-generated viruses that can infect cells in a CD4-independent manner are still susceptible to inhibition by BMS-626529. The proposed mechanism for CD4 independence in the ADA laboratory-generated virus76,77 suggests that the presence of the gp120 substitutions S190R and N197S shifts the equilibrium away from the native gp120 UNLIG (Fig. 10:1) state and toward the pCD4 (Fig. 10:2), bCD4 (Fig. 10:3), and gp120 LIG CD4-independent states (Fig. 10:5). It is postulated that this shift is due to the loss of the N197 glycosylation site and concomitant destabilization of the interactions between the V1/V2/V3 loops, which results in enhanced sampling of the V1/V2 loops. The increased sampling of the V1/V2 loops is likely to result in a large enough population of gp120 in the CD4-independent state (Fig. 10:5) where the stem of the V1/V2 loop (β2–β3 sheet) is complemented with the β20–β21 sheet in order to allow formation and unmasking of the chemokine receptor binding site and CD4-independent binding. Therefore, we propose that BMS-626529 can inhibit both CD4-induced and CD4-independent formation of the liganded “open state” four-stranded bridging sheet and the subsequent formation and exposure of the chemokine receptor binding site.

In conclusion, we have built a series of models based on known X-ray structures that represent different conformations of HIV-1 gp120. BMS-626529 was docked into the various models, which were refined and evaluated using MD simulations. The stable MD models,
supported by AI SAR analyses, substitutions that affect susceptibility to AIs, and biochemical and biophysical data, were used to predict that BMS-626529 binds to the unliganded (UNLIG) gp120 structure within the structurally conserved outer domain, just underneath the β20–β21 sheet and adjacent to the CD4 binding loop. By binding to this site, we propose that BMS-626529 inhibits both CD4-induced and -independent formation of the four-stranded bridging sheet and subsequent formation and exposure of the co-receptor binding site. This unique mechanism of action prevents the initial interaction of the virus with CD4+ T cells and is distinct from that of currently available entry inhibitors, which target chemokine co-receptor binding and viral/cell membrane fusion, following binding of HIV-1 to the CD4 cell. This offers a novel therapeutic approach, broadening the range of antiretroviral therapies available for treatment of HIV-1 infection, particularly for patients with limited therapeutic options. BMS-626529 is currently being investigated clinically through the use of the prodrug BMS-663068, and a Phase IIb study of BMS-663068 in HIV-1-infected treatment-experienced subjects is ongoing (NCT01384734).

ACKNOWLEDGMENTS

The authors thank the numerous researchers within the Research and Development team at Bristol-Myers Squibb, including Hsu-Tso Ho, Pin-Fang Lin, Richard Colombo, and J.J. Kim Wright, who contributed to the development and progression of the attachment inhibitor series. Editorial assistance was provided by Anna Sirirazi at MediTech Media and was funded by Bristol-Myers Squibb.

REFERENCES

1. Adamson CS, Freed EO. Novel approaches to inhibiting HIV-1 replication. Antiviral Res 2010;85:119–141.
2. Bhattacharya S, Osman H. Novel targets for anti-retroviral therapy. J Infect 2009;59:377–386.
3. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, Koff WC, Courter JR, Smith III AB, Kwong PD, Blanchard SC, Mothes W. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 2014;346:759–763.
4. Lobritz MA, Ratcliff AN, Arts EJ, HIV-1 entry, inhibitors, and resistance. Viruses 2010;2:1069–1105.
5. Kadow JF, Langley DR, Meanwell NA, Pracitto M, Walker M, Yeung K. Protein-protein interaction targets to inhibit HIV-1 infection. In: Wemd M, editor. Topics in medicinal chemistry, Vol. 8: Protein-protein interactions. Springer, London; 2012. pp 105–166.
6. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006;24:739–769.
7. Guttman M, Kahn M, Garcia NK, Hu SL, Lee KK. Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120. J Virol 2012;86:8750–8764.
8. Chen B, Vogan EM, Gong H, Skelhel JJ, Wiley DC, Harrison SC. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005;433:834–841.
9. Kwon YD, Finzi A, Wu X, Dogo-Isong-Jie C, Lee DK, Moore LR, Schmidt SD, Stucy J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci USA 2012;109:5663–5668.
10. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648–659.
11. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkins D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013;342:1477–1483.
12. Davenport TM, Guttman M, Guo W, Cleveland B, Kahn M, Hu SL, Lee KK. Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. J Virol 2013;87:10855–10873.
13. Guttman M, Garcia NK, Cupo A, Matsui T, Julien JP, Sanders RW, Wilson IA, Moore JP, Lee KK. CD4-induced activation in a soluble HIV-1 env trimer. Structure 2014;22:974–984.
14. Guo Q, Ho HT, Dicker I, Fan L, Zhou N, Frierobt J, Wang T, McAuliffe BV, Wang HG, Rose RE, Fang H, Scarntati HT, Langley DR, Meanwell NA, Abraham R, Colombo RI, Lin PF. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 2013;77:10528–10536.
15. Ho HT, Fan L, Nowicka-Sans B, McAuliffe B, Li CB, Yamanaka G, Zhou N, Fang H, Dicker I, Dalterio R, Gung YF, Wang T, Yin Z, Ueda Y, Matsikella J, Kadow J, Clapham P, Robinson J, Colombo R, Lin PF. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J Virol 2006;80:4017–4025.
16. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gung YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Dennimie C, Demers G, Yang Z, Zadura LM, Meanwell NA, Colombo R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003;100:11013–11018.
17. Wang T, Zhang Z, Wallace OB, Deshpande M, Fang H, Yang Z, Zadura LM, Tweedie DL, Huang S, Zhao F, Ranadive S, Robinson BS, Gong YF, Ricardi K, Spicer TP, Denimie C, Rose R, Wang HG, Blair WS, Shi PY, Lin PF, Colombo RI, Meanwell NA. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl]-oxoacetyl]-2-(R)-methylperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003;46:4236–4239.
18. Wang T, Yin Z, Zhang Z, Bender JA, Yang Z, Johnson G, Yang Z, Zadura LM, D’Arienzo CJ, DiGiugno PD, Gesenberg C, Yamanaka GA, Gung YF, Ho HT, Fang H, Zhou N, McAuliffe BV, Eggis BJ, Fan L, Nowicka-Sans B, Dicker IB, Gao Q, Colombo RJ, Lin PF, Meanwell NA, Kadow JF. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylperazine (BMS-378806): a novel HIV-1 attachment inhibitor that prevents gp120 binding and downstream entry events. C&EN 2014;92:14–21.
19. Wang T, Wang T, Yin Z, Zhang Z, Bender JA, Yang Z, Johnson G, Yang Z, Zadura LM, D’Arienzo CJ, DiGiugno PD, Gesenberg C, Yamanaka GA, Gung YF, Ho HT, Fang H, Zhou N, McAuliffe BV, Eggis BJ, Fan L, Nowicka-Sans B, Dicker IB, Gao Q, Colombo RJ, Lin PF, Meanwell NA, Kadow JF. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylperazine (BMS-388043): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003;46:4236–4239.
20. Wang T, Yin Z, Zhang Z, Bender JA, Yang Z, Johnson G, Yang Z, Zadura LM, D’Arienzo CJ, DiGiugno PD, Gesenberg C, Yamanaka GA, Gung YF, Ho HT, Fang H, Zhou N, McAuliffe BV, Eggis BJ, Fan L, Nowicka-Sans B, Dicker IB, Gao Q, Colombo RJ, Lin PF, Meanwell NA, Kadow JF. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylperazine (BMS-378806): a novel HIV-1 attachment inhibitor that prevents gp120 binding and downstream entry events. C&EN 2014;92:14–21.
21. Brown J, Chien C, Timmins P, Dennis A, Doll W, Sandefur E, Page R, Netles RE, Zhu L, Grasela D. Compartmental absorption model.
extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodruk. J Pharm Sci 2013;102:1742–1751.

23. Kadov J, Wang HG, Lin PF. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr Opin Investig Drugs 2006;7:721–726.

24. Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF, Ray N, Wind-Rotolo M, Zhi L, Majumdar A, Stock D, Latalaide M, Hanna GJ, Matsikella JD, Ueda Y, Wang T, Kadov JE, Meanwell NA, Krystal M. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodruk BMS-663068. Antimicrob Agents Chemother 2012;56:3498–3507.

25. Nettles R, Schumann D, Zhu L, Stonier M, Huang S-P, Chang I, Chien C, Crystal M, Wind-Rotolo M, Ray N, Hanna GJ, Bertz R, Grasela DM. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis 2012;206:1002–1011.

26. Ray N, Hwang C, Healy MD, Whitcomb J, Lataillade M, Wind-Rotolo M, Crystal M, Hanna GJ. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodruk BMS-663068. J Acquir Immune Defic Syndr 2013;64:7–15.

27. Zhou N, Nowicka-Sans B, McAuliffe B, Ray N, Eggers B, Fang H, Fan L, Healy M, Langley DR, Hwang C, Latalaide M, Hanna GJ, and Krystal M. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodruk BMS-663068; J Antimicrob Chemother 2014;69:573–581.

28. Si Z, Madani N, Cox JM, Chruma JJ, Klein JC, Schellin S, Chaien I, Freire E, Smith AB, III, Sodroski JG. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci USA 2004;101:5036–5041.

29. Xiao P, Usami O, Suzuki Y, Ling H, Shimizu N, Hoshino H, Zhuang M, Ashino Y, Gu H, Hattori T. Characterization of a CD4-receptor-induced conformational changes in the viral envelope glycoprotein. J Virol 2004;78:1243–1255.

30. Li Z, Zhou N, Sun Y, Ray N, Latalaide M, Hanna GJ, Crystal M. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodruk BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrob Agents Chemother 2013;57:4172–4180.

31. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008;455:109–113.

32. Zerlouhi B, Nelson JA, Saha K. Isolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium-inducing and acutely cytopathic for CD8+ lymphocytes. J Virol 2004;78:1423–1425.

33. Li Z, Zhou N, Sun Y, Ray N, Latalaide M, Hanna GJ, Crystal M. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodruk BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrob Agents Chemother 2013;57:4172–4180.

34. Meyerson JR, Tran EE, Kiyedba O, Chen W, Dimitrov DS, Gorlani A, Verrips T, Lisson JD, Subramaniam S. Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc Natl Acad Sci USA 2013;110:513–518.

35. Khayat R, Lee JH, Julien JP, Cupo A, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013;342:1484–1490.

36. Wang T, Zhang Z, Meanwell NA, Kadov JF, Yin Z, Preparation and antiviral activity for substituted indoleazaindoles. U.S. Patent WO 2002/017617, 2002.

37. Wang T, Zhang Z, Meanwell NA, Kadov JE, Yin Z, Xue QM, Ren AR, Matsikella JD, Ueda Y. Composition and antiviral activity of substituted azaindoles. U.S. Patent US 2,004,011,078,5A1, 2004.

38. Kadov JF, Meanwell NA, Wang T, Yin Z, Zhang Z. Composition and antiviral activity of substituted indoleazaindoles. U.S. Patent 2,002,000,455, 2002.

39. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000;28:233–242.

40. Huang CC, Tang M, Zhang MY, Majeed S, Montamban E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. Structure of a V3-containing HIV-1 gp120 core. Science 2005;310:1025–1028.

41. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, Kong L, Kwon YD, Stuecky J, Zhou T, Robinson JE, Schief WR, Sodroski J, Wyatt R, Kwong PD. Structure of HIV-1 gp120 with gp41-interaction region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 2010;107:1166–1171.

42. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Peichi R, Sastry M, Dai K, O’Dell S, Patel N, Shahzad-ul-Hassan S, Yang Y, Zhang Z, Zhou T, Zhu J, Boyington JC, Chuan GE, Dianji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Capiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orweno J, Wang L, Arthos J, Belyaev CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011;480:336–343.

43. Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesier RA. A hierarchical approach to all-atom protein loop prediction. Proteins 2004;55:351–367.

44. Shrivastava IH, Wendel K, LaLonde JM. Spontaneous rearrangement of the B20/B21 strands in simulations of unfolded HIV-1 glycoprotein, gp120. Biochemistry 2012;51:7783–7793.

45. Madani N, Perdigao AL, Srinivasan K, Cox JM, Chruma J, LaLonde J, Head J, Smith AB, III, Sodroski JG. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol 2004;78:3742–3752.

46. Wang T, Kadov JE, Zhang Z, Yin Z, Gao Q, Wu D, Parker DD, Yang Z, Zadljura I, Robinson BA, Gong YF, Spicer TP, Blair WS, Shi PY, Yamanaka G, Lin PF, Meanwell NA. Inhibitors of HIV-1 attachment. Part 4: a study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorg Med Chem Lett 2009;19:5140–5145.

47. Regueiro-Ren A, Xue QM, Swiderski JJ, Gong YF, Mathew M, Parker DD, Yang Z, Eggers B, D’Arienzo C, Sun Y, Malinowski J, Gao Q, Wu D, Langley DR, Coltono RJ, Grasela DM, Zheng M, Lin PF, Meanwell NA, Kadov JE. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 12. structure-activity relationships associated with 4-fluoro-6-azaindoles derivatives leading to the identification of 1-(4-benzoyl-piperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1H-pyridin-2,3-c-yl)-phenyl-2,1-dione (BMS-585248). J Med Chem 2013;56:1656–1669.

48. Meanwell NA, Wallace OB, Fang H, Wang H, Deshpande M, Wang T, Yin Z, Zhang Z, Pearce BC, James J, Yeung KS, Qiu Z, Kim Wright JJ, Yang Z, Zadljura I, Tweedie DL, Yeola S, Zhao F, Ranadive S, Robinson BA, Gong YF, Wang HG, Spicer TP, Blair WS, Shi PY, Colonno RJ, Lin PF. Inhibitors of HIV-1 attachment. Part 2: an initial survey of indole substitution patterns. Bioorg Med Chem Lett 2009;19:1977–1981.
51. Meanwell NA, Wallace OB, Wang H, Deshpande M, Pearson BC, Trehan A, Yeung KS, Qiu Z, Wright JJ, Robinson BA, Gong YF, Wang HG, Spicer TP, Blair WS, Shi PY Lin PF. Inhibitors of HIV-1 attachment. Part 3: a preliminary survey of the effect of structural variation of the benzamide moiety on antiviral activity. Bioorg Med Chem Lett 2009;19:5136–5139.

52. Halgren TA, Murphy RB, Friess RA, Beard HS, Frey LL, Pollard WT, Banks JL. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–1759.

53. Friess RA, Banks JL, Murphy RB, Halgren TA, Klicic JI, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–1749.

54. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926–935.

55. Nelson MT, Humphrey W, Gursoy A, Dalke A, Kale L, Skeel RD, Schulten K. NAMD: a parallel, object-oriented molecular dynamics program. J Supercomput Appl High Perform Comput 1996;10:251–268.

56. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26:1781–1802.

57. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006;65:712–725.

58. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, Shaw DE. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 2010;78:1950–1958.

59. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem 2004;25:1157–1174.

60. Skeel RD. Symplectic integration with variable stepsize. Ann Numer Math 1994;1:191–198.

61. Ryckaert J-P, Ciccotti G, Berendsen HJC. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977;23:327–341.

62. Darden T, York D, Pedersen L. Particle mesh Ewald: an N-log(N) method for Ewald sums in large systems. J Chem Phys 1993;98:10089–10092.

63. Petersen HG. Accuracy and efficiency of the particle mesh Ewald method. J Chem Phys 1995;103:3668–3679.

64. R Core Team. R: a language and environment for statistical computing, Vienna, Austria: R Foundation for Statistical Computing, 2012.

65. Zhou N, Nowicka-Sans B, Zhang S, Fan L, Fang J, Fang H, Gong YF, Eggers B, Langley DR, Wang T, Kadow J, Grasela D, Hanna GJ, Alexander L, Colonnro R, Krystal M, Lin PE. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Antimicrob Agents Chemother 2011;55:729–737.

66. Wang T, Kadow JF, Meanwell NA, Yeung K-S, Zhang Y, Yin Z, Qiu Z, Deon DH, James CA, Ruediger EH, Bachand C. Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides. U.S. Patent 2,004,018,629,2A1, 2004.

67. Yeung KS, Qiu Z, Xue Q, Fang H, Yang Z, Zadura L, D’Arienzo CJ, Eggers BJ, Riccardi K, Shi PY, Gong YF, Browning MR, Gao Q, Hansel S, Santone K, Lin PF, Meanwell NA, Kadow JF. Inhibitors of HIV-1 attachment. Part 7: indole-7-carboxamides as potent and orally bioavailable antiviral agents. Bioorg Med Chem Lett 2013;23:198–202.

68. Sato S, Inokuma T, Otsuno B, Burton DR, Babas CF, III. Chemically programmed antibodies as HIV-1 attachment inhibitors. ACS Med Chem Lett 2013;4:460–465.

69. Parker CG, Dahlgren MK, Tao RN, Li DT, Douglass EF Jr, Shota T, Jawanda N, Spasov KA, Lee S, Zhou N, Domaosal RA, Sutton RE, Anderson KS, Krystal M, Jorgensen WL, and Spiegel DA. Illuminating HIV gp120-ligand recognition through computationally-driven optimization of antibody recruiting molecules. Chem Sci 2014;5:2311–2317.

70. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, Doyle ML. Energmetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA 2000;97:9026–9031.

71. Curreli F, Kwon YD, Zhang H, Yang Y, Scacalossi D, Kwong PD, Debnath AK. Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by x-ray structure and resistance study. Antimicrob Agents Chemother 2014;58:3478–5491.

72. Da LT, Quan JM, Wu YD. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry. Proteins 2011;79:1810–1819.

73. Kong R, Tan JJ, Ma XH, Chen WZ, Wang CX. Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation. Biochim Biophys Acta 2006;1764:766–772.

74. Drora RO, Pana AC, Arlowa DH, Borhania DW, Maragakisa P, Shana Y, Xua H, Shawa DE. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc Natl Acad Sci USA 2011;108:13118–13123.

75. Yao M, Wang L, Gu C, Herschhorn A, Desormeaux A, Finzi A, Xiang S, Sodroski JG. Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci USA 2013;110:12438–12443.

76. Kolchinsky P, Mizrabekov T, Farzan M, Kiprilov E, Cayabab M, Mooney LJ, Choe H, Sodroski J. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 1999;73:8120–8126.

77. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol 2001;75:3435–3443.